Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Emend (aprepitant/fosaprepitant by Quarter
Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — Worldwide sales ($M) ($M)
Merck Emend (aprepitant/fosaprepitant: $30M in Q4 2020, down 42.3% from a year earlier. That is the lowest of the 16 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2020 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2021-02-25) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2020 | Dec 31, 2020 | 30 | -42.3% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 39 | -60.2% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 33 | -72.7% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 43 | -63.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 52 | -58.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 98 | -20.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 121 | -18.2% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 117 | -6.4% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 126 | -11.9% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 123 | -10.2% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 148 | +3.5% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 125 | -6.0% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 143 | – | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 137 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 143 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 133 | – | Form 10-Q (filed 2018-05-08) ↗ |
Breakdown
What makes up emend (aprepitant/fosaprepitant
Cite this data
StockData. (2026). Merck Emend (aprepitant/fosaprepitant ($M), quarterly Q1 2017–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-emend
See every metric in the Merck KPI table. Data updated Oct 26, 2026.